Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871 is registered in ClinicalTrials.gov with Radiopharm Theranostics, Ltd as lead sponsor.

NCT NCT07189871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07189871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Lead sponsor
Radiopharm Theranostics, Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 23, 2026
Completion date
December 31, 2027
Enrollment
61 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer (crpc), cervical cancer, colorectal cancer, endometrial cancer, esophageal squamous cell carcinoma (escc), head & neck squamous cell carcinoma (hnscc), nsclc (non-small cell lung cancer), ovarian cancer, sarcoma, small cell lung cancer (sclc ), tnbc, triple negative breast cancer